

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

### **翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3692)**

## **VOLUNTARY ANNOUNCEMENT LICENSING AGREEMENT WITH BIOTHEUS**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on March 14, 2024, Hansoh (Shanghai) Healthtech Company Limited \* (翰森(上海)健康科技有限公司) (the “**Licensee**”), a wholly-owned subsidiary of the Company, entered into a license agreement (the “**Licensing Agreement**”) with Biotheus Inc.\* (“**Biotheus**”).

Pursuant to the Licensing Agreement, the Licensee obtained an exclusive license from Biotheus to use HS-20117 (license-in as PM1080) for the development, production, and commercialization of bispecific antibody-drug conjugate product (the “**ADC Product**”) on a global basis, with the right of sublicense. The Licensee will pay an upfront payment and potential payments based on the ADC Product development, registration and sales-based commercialisation milestones of up to RMB5 billion in aggregate, as well as tiered royalties based on global net sales.

### **ABOUT HS-20117/PM1080**

HS-20117/PM1080 is a 1+1 heterodimeric structure of EGFR/cMet bispecific antibody, which can inhibit the growth and survival of tumors by specifically targeting the tumor antigens EGFR and cMet, and is currently in phase I clinical trials.

As disclosed in the announcement of the Company dated on November 14, 2022, the Licensee entered into a license agreement (the “**2022 Licensing Agreement**”) with Biotheus. Pursuant to the 2022 License Agreement, the Licensee obtained an exclusive license from Biotheus to develop and commercialize HS-20117/PM1080 within China (including Hong Kong, Macau and Taiwan). This additional license will further enrich the Group’s research and development pipeline.

## **ABOUT BIOTHEUS**

Incorporated in 2018, Biotheus is a clinical-stage biopharmaceutical company focused on the development of innovative biologics in the areas of malignancies and autoimmune diseases. To the best knowledge and belief of the Company, Biotheus is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under Listing Rules.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, March 14, 2024

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* *For identification purposes only*